Another win in Merck’s column
TEXT OF STORY
SCOTT JAGOW: Another Vioxx trial is over and again the company that made the painkiller won. Merck has prevailed in more than half the suits so far, but there are many more to go. Helen Palmer reports from the Health Desk at WGBH.
HELEN PALMER: A jury in Atlantic City decided that Vioxx was not responsible for the heart attack a 68-year-old New Jersey woman suffered in 2004.
The jury found that, though Merck didn’t warn patients of the cardiac dangers of VIOXX, the company didn’t market the drug dishonestly.
Merck’s now won four of the seven suits to come to trial, but legal experts say it’s too soon to crow.
BENJAMIN ZIPURSKY: I don’t think Merck or its investors should get all that excited about this victory, because if they couldn’t win this case then that would really look serious.
Fordham Law School’s Benjamin Zipursky says this case was very weak, as the plaintiff had many risk factors for a heart attack besides taking Vioxx.
Analysts say they don’t believe this victory alters the risks for the company. About 16,000 suits have been filed in connection with Vioxx, and strong cases are still likely to win, so Merck could face billions of dollars of liability.
In Boston, I’m Helen Palmer for Marketplace.
Stories You Might Like
There’s a lot happening in the world. Through it all, Marketplace is here for you.
You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible.
Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.
